CRISPR Therapeutics AG

Common Name

CRISPR Therapeutics

Country

Switzerland

Sector

Healthcare

Industry

Biotechnology

Employees

393

Ticker

CRSP

Exchange

NASDAQ/NMS

Website

crisprtx.com

Description

Crispr Therapeutics AG is a pioneering biotechnology company specializing in gene editing. Its primary function is to advance the development and application of CRISPR/Cas9 technology, which allows fo... Show more

Financial Statements of CRISPR Therapeutics

Below are the financial statements of CRISPR Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	298.26^a	389.48^a
Marketable securities	1,605.57^a	1,304.22^a
Accounts receivable	25^a	200^a
Prepaid expenses and other current assets	8.31^a	14.39^a
Total current assets	1,937.13^a	1,908.08^a
Assets	—	—
Property and equipment, net	134.09^a	151.95^a
Marketable securities, non-current	0^a	1.97^a
Intangible assets, net	0^a	0.02^a
Restricted cash	11.52^a	11.59^a
Operating lease assets	143.46^a	153.99^a
Other non-current assets	15.83^a	1.98^a
Total assets	2,242.03^a	2,229.57^a
Current liabilities	—	—
Accounts payable	14.71^a	38.15^a
Accrued expenses	41.07^a	45.34^a
Deferred revenue, current	3.85^a	4.11^a
Accrued tax liabilities	0.45^a	0.44^a
Operating lease liabilities	17.29^a	15.63^a
Other current liabilities	10.42^a	5.14^a
Total current liabilities	87.78^a	108.79^a
Deferred revenue, non-current	12.32^a	14.01^a
Operating lease liabilities, net of current portion	206.41^a	223.01^a
Other non-current liabilities	3.44^a	0.96^a
Total liabilities	309.95^a	346.77^a
Shareholders’ equity	—	—
Common shares	2.7^a	2.5^a
Treasury shares, at cost	-0.06^a	-0.06^a
Additional paid-in capital	3,293.56^a	2,878.16^a
Accumulated deficit	-1,365.95^a	-999.7^a
Accumulated other comprehensive income	1.84^a	1.91^a
Total shareholders’ equity	1,932.08^a	1,882.8^a
Total liabilities and shareholders’ equity	2,242.03^a	2,229.57^a

Download Data

Verified Sources Behind CRISPR Therapeutics’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore CRISPR Therapeutics’s data sources below and access millions more through our Disclosure Search.

a. CRISPR Therapeutics's Annual Report 2024

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

CRISPR Therapeutics AG

Financial Statements of CRISPR Therapeutics

Verified Sources Behind CRISPR Therapeutics’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

BeOne Medicines AG

Lonza Group AG

Tecan Group AG

Roche Holding AG

Galenica AG

Straumann Holding AG